Dariohealth Corp Stock Price, News & Analysis

DarioHealth (NASDAQ: DRIO) announced 34 new employer clients in the past two weeks, bringing 79 clients signed year-to-date, surpassing its 2025 target of 40 new clients by 98%. The new agreements cover tens of thousands of lives and are expected to start contributing to revenue in Q1 2026. Nearly all new clients selected Dario for integrated cardiometabolic care. The company cites clinical outcomes including a 1.4% eHbA1c reduction, 38% blood pressure reduction by one stage, and 10% average BMI reduction. A recent JMIR real-world study with Sanofi and Symphony Health reported 23% lower hospitalization rates and 26% lower all-cause charges for Dario users versus matched usual-care individuals.

DarioHealth (NASDAQ: DRIO) announced publication of a peer-reviewed retrospective cohort study in Journal of Medical Internet Research showing estimated real-world savings and lower utilization for adults with type 2 diabetes using the Dario digital health platform versus matched usual-care individuals.

Key findings: 23.5% lower inpatient hospitalization rates, 26% lower all-cause healthcare resource utilization charges, and an estimated $5,077 gross medical cost savings per patient per year. The 12-month analysis covered 2,445 Dario users vs 7,334 matched controls and reported shorter lengths of stay, lower 30-day readmissions, and a dose-response link between engagement and fewer inpatient/ER events.

DarioHealth (NASDAQ: DRIO) reported third-quarter 2025 results: Q3 revenue $5.0M versus $7.4M a year earlier and $5.4M in Q2 2025. The company cites a strategic shift from one-time sales to high-margin ARR, reporting 60% GAAP gross margin and ~80% non-GAAP gross margin on its B2B2C channel. Dario added 45 new ARR clients year-to-date, exceeded its 2025 goal, and holds a $69M 2026 pipeline while targeting $12.4M in new business. Cash on hand was $31.9M after a $17.5M private placement; management expects cashflow breakeven in late 2026–early 2027.

DarioHealth (NASDAQ: DRIO) presented real‑world claims research at ISPOR Europe 2025 showing a pre‑post reduction in total medical costs among employer members using its multi‑condition digital health platform, with the largest effects in high‑risk populations. The retrospective analysis links Dario's integrated solution—connected devices, AI insights and human coaching—to measurable economic impact and improved population health outcomes.

The company said this is its first claims‑data publication and noted deployment across employers and health plans in the U.S. supporting diabetes, hypertension, weight, musculoskeletal and behavioral health.

DarioHealth (NASDAQ: DRIO) will report results for the third quarter ended September 30, 2025 and host a conference call and webcast on Thursday, November 13, 2025 at 8:30 a.m. ET, before the market opens.

Executives on the call: Erez Raphael (CEO), Steven Nelson (President & Chief Commercial Officer), and Chen Franco-Yehuda (CFO). Webcast and dial-in details are provided; a replay will be available through Thursday, November 27, 2025.

Dario (NASDAQ: DRIO) announced six new employer clients on Oct 13, 2025, adding tens of thousands of covered employees and expanding across manufacturing, education, advertising and professional services.

The company highlighted a value-based pricing model that ties payments to member engagement and clinical progress; 3 of 6 new contracts use this milestone-based framework. Dario cited a platform 5X ROI and ~$5,000 annual savings per user, plus 92 peer-reviewed studies supporting outcomes. New clients include a building materials employer with >6,000 U.S. employees and a public-school district with >40,000 staff.

DarioHealth (NASDAQ: DRIO) announced a strategic collaboration with OneStep on Oct 6, 2025 to integrate OneStep's FDA-listed smartphone-only clinical-grade fall risk assessment into Dario's multi-condition digital health platform. The parties signed a Memorandum of Understanding (MOU) and expect to finalize a Master Services Agreement in the coming weeks. The integration aims to identify fall risk among high-risk groups (including members with obesity and Medicare Advantage populations), improve engagement and independence, and drive measurable ROI for self-insured employers and health plans. The release cites falls as a >$50 billion annual direct medical cost and notes the US fall management market was ~$200 million in 2024, projected to exceed $300 million by 2033 (CAGR >5%).

DarioHealth (NASDAQ:DRIO), a digital health solutions provider for chronic condition management, has initiated a comprehensive strategic review following multiple unsolicited inquiries from interested parties. The company's Board has formed a Special Committee and engaged Perella Weinberg Partners as financial advisor to evaluate potential opportunities including a sale, merger, or strategic business combination.

In recent developments, Dario has completed an oversubscribed $17.5 million private placement, bringing its pro forma cash position to approximately $40 million as of Q2 2025. The company has also optimized its capital structure by converting outstanding preferred shares into common stock and equivalents, creating a more transparent equity structure.

DarioHealth (NASDAQ: DRIO), a global digital health market leader, has announced a $17.5 million private placement of common stock. The company will sell 2,713,180 shares at $6.45 per share, with the offering expected to close around September 23, 2025.

The private placement is being conducted under Section 4(a)(2) of the Securities Act and Regulation D, with the company committing to file a registration statement with the SEC for the resale of the shares. The proceeds will be used for general corporate purposes.